{"id":"liposomal-cytarabine-daunorubicin-for-injection","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression (neutropenia, thrombocytopenia)"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Mucositis"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Cardiotoxicity"},{"rate":null,"effect":"Neurotoxicity (cytarabine syndrome)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cytarabine is a nucleoside analog that inhibits DNA polymerase and blocks DNA synthesis, while daunorubicin is a topoisomerase II inhibitor that causes DNA strand breaks. The liposomal encapsulation allows preferential uptake by leukemic blasts, particularly in the central nervous system, improving drug delivery and reducing systemic toxicity to normal tissues.","oneSentence":"This liposomal formulation delivers cytarabine and daunorubicin directly into leukemic cells, where both drugs inhibit DNA synthesis and induce apoptosis.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:19:06.173Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute myeloid leukemia (AML)"},{"name":"Acute lymphoblastic leukemia (ALL)"},{"name":"Lymphomatous meningitis"}]},"trialDetails":[{"nctId":"NCT05564390","phase":"PHASE2","title":"MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-06-18","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy","enrollment":2000},{"nctId":"NCT05554419","phase":"PHASE2","title":"Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial)","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-07-01","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia Arising From Previous Myeloproliferative Neoplasm","enrollment":184},{"nctId":"NCT05554406","phase":"PHASE2","title":"Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-09-25","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy","enrollment":335},{"nctId":"NCT05627232","phase":"PHASE1","title":"Tazemetostat and Palbociclib With CPX-351for R/R AML","status":"RECRUITING","sponsor":"Thomas Jefferson University","startDate":"2023-08-28","conditions":"Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia","enrollment":24},{"nctId":"NCT03226418","phase":"PHASE2","title":"Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2017-07-07","conditions":"Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia","enrollment":75},{"nctId":"NCT02286726","phase":"PHASE2","title":"CPX-351 in Treating Patients With Newly Diagnosed, High-Risk Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-05-04","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Secondary Acute Myeloid Leukemia","enrollment":56},{"nctId":"NCT04293562","phase":"PHASE3","title":"A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2020-07-21","conditions":"Acute Myeloid Leukemia","enrollment":1186},{"nctId":"NCT03896269","phase":"PHASE1","title":"CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-05-14","conditions":"Blasts 10-19 Percent of Bone Marrow Nucleated Cells, Blasts More Than 5 Percent of Bone Marrow Nucleated Cells, High Risk Chronic Myelomonocytic Leukemia","enrollment":38},{"nctId":"NCT03629171","phase":"PHASE2","title":"Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-10-29","conditions":"Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia","enrollment":52},{"nctId":"NCT03672539","phase":"PHASE2","title":"Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-11-07","conditions":"Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, High Risk Myelodysplastic Syndrome","enrollment":50},{"nctId":"NCT04915612","phase":"PHASE1","title":"Liposomal Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin for the Treatment of Relapsed Refractory Pediatric Patients With Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-05-21","conditions":"Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia","enrollment":1},{"nctId":"NCT04269213","phase":"PHASE2","title":"CPX-351 for the Treatment of Secondary Acute Myeloid Leukemia in Patients Younger Than 60 Years Old","status":"ACTIVE_NOT_RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2021-07-29","conditions":"Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Secondary Acute Myeloid Leukemia","enrollment":21},{"nctId":"NCT04802161","phase":"PHASE2","title":"Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related Changes","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-08-24","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Post Cytotoxic Therapy, Acute Myeloid Leukemia With Multilineage Dysplasia","enrollment":50},{"nctId":"NCT04128748","phase":"PHASE1, PHASE2","title":"Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-05-27","conditions":"Acute Myeloid Leukemia, Blasts More Than 10 Percent of Bone Marrow Nucleated Cells, High Risk Myelodysplastic Syndrome","enrollment":52},{"nctId":"NCT04493164","phase":"PHASE2","title":"CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-12-30","conditions":"Acute Myeloid Leukemia With Gene Mutations, Myelodysplastic Syndrome, Myeloproliferative Neoplasm","enrollment":30},{"nctId":"NCT03878199","phase":"PHASE1, PHASE2","title":"Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms","status":"COMPLETED","sponsor":"Ohio State University Comprehensive Cancer Center","startDate":"2019-02-20","conditions":"Essential Thrombocythemia, Myelofibrosis, Myeloproliferative Neoplasm","enrollment":12},{"nctId":"NCT03860844","phase":"PHASE2","title":"Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia","status":"TERMINATED","sponsor":"Sanofi","startDate":"2019-08-06","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia","enrollment":67},{"nctId":"NCT07156435","phase":"PHASE1","title":"Vyxeos® With Clofarabine for Pediatric AML","status":"RECRUITING","sponsor":"Princess Maxima Center for Pediatric Oncology","startDate":"2020-11-06","conditions":"Relapsed Pediatric AML, Refractory Pediatric AML","enrollment":25},{"nctId":"NCT04195945","phase":"PHASE2","title":"CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms in Medically Less-Fit Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2020-03-11","conditions":"Acute Myeloid Leukemia, Myeloid Neoplasm","enrollment":60},{"nctId":"NCT06770257","phase":"PHASE2","title":"Daunorubicin, Cytarabine Liposomes Plus Venetoclax vs Azacitidine Plus Venetoclax in AML Patients Unfit for Intensive Chemotherapy","status":"WITHDRAWN","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-12-10","conditions":"Leukemia, Myeloid, Acute","enrollment":""},{"nctId":"NCT03844997","phase":"PHASE1, PHASE2","title":"Phase I/II Trial of CPX-351 + Palbociclib in Patients With Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Sudipto Mukherjee, MD, PhD, MPH","startDate":"2019-06-06","conditions":"Acute Myeloid Leukemia, AML","enrollment":35},{"nctId":"NCT04049539","phase":"PHASE1, PHASE2","title":"Vyxeos for Re-induction Treatment of Acute Myeloid Leukemia Patients With Persistent Disease After Induction","status":"RECRUITING","sponsor":"Ohio State University Comprehensive Cancer Center","startDate":"2021-01-29","conditions":"Blasts More Than 5 Percent of Bone Marrow Nucleated Cells, Persistent Disease, Refractory Acute Myeloid Leukemia","enrollment":28},{"nctId":"NCT05599360","phase":"PHASE2","title":"Vyxeos for Induction of Low- or Intermediate-risk.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shaare Zedek Medical Center","startDate":"2022-08-07","conditions":"Leukemia, Myeloid, Acute","enrollment":20},{"nctId":"NCT06221683","phase":"PHASE2","title":"Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML","status":"RECRUITING","sponsor":"Children's Hospital of Soochow University","startDate":"2024-01-01","conditions":"AML, Childhood, Acute Myeloid Leukemia","enrollment":500},{"nctId":"NCT04526288","phase":"PHASE2","title":"CPX-351 Versus Immediate Stem Cell Transplantation for the Treatment of High-Grade Myeloid Cancers With Measurable Residual Disease","status":"TERMINATED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2021-08-09","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts-2, Myeloid Neoplasm","enrollment":1},{"nctId":"NCT06182592","phase":"PHASE3","title":"A Bridging Study of Liposomal Cytarabine-Daunorubicin in Treating Olderly Patients With Treatment-naive High-Risk (Secondary) Acute Myeloid Leukemia","status":"NOT_YET_RECRUITING","sponsor":"CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.","startDate":"2024-01","conditions":"High-risk (Secondary) Acute Myeloid Leukemia","enrollment":120},{"nctId":"NCT03904251","phase":"PHASE1","title":"CPX-351 and Gemtuzumab Ozogamicin in Treating Patients With Relapsed Acute Myeloid Leukemia","status":"TERMINATED","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2019-07-18","conditions":"Acute Myelogenous Leukemia","enrollment":13},{"nctId":"NCT03825796","phase":"PHASE2","title":"CPX-351 Plus Enasidenib for Relapsed AML","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2019-04-12","conditions":"Recurrent Acute Myeloid Leukemia","enrollment":2},{"nctId":"NCT05801835","phase":"NA","title":"A Bioequivalence Study of (Cytarabine: Daunorubicin) Liposome for Injection","status":"UNKNOWN","sponsor":"CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.","startDate":"2023-08-25","conditions":"Acute Myeloid Leukemia","enrollment":36},{"nctId":"NCT02642965","phase":"PHASE1, PHASE2","title":"Liposome-encapsulated Daunorubicin-Cytarabine, Fludarabine Phosphate, Cytarabine, and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2016-05-02","conditions":"Acute Myeloid Leukemia Post Cytotoxic Therapy, Recurrent Childhood Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia","enrollment":38},{"nctId":"NCT05320380","phase":"PHASE1, PHASE2","title":"A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Treat","status":"WITHDRAWN","sponsor":"Children's Oncology Group","startDate":"2023-08-01","conditions":"Recurrent Acute Myeloid Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent Mixed Phenotype Acute Leukemia","enrollment":""},{"nctId":"NCT03878927","phase":"PHASE1","title":"CPX-351+GO in Subjects 55 Years Old, or Older, With AML","status":"TERMINATED","sponsor":"Weill Medical College of Cornell University","startDate":"2019-08-23","conditions":"Acute Myeloid Leukemia","enrollment":11},{"nctId":"NCT01319981","phase":"PHASE2","title":"Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2013-03-05","conditions":"Leukemia","enrollment":31},{"nctId":"NCT00299182","phase":"PHASE1, PHASE2","title":"Study of AMG 531 to Evaluate the Safety & Efficacy in Patients With Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2006-03","conditions":"Lymphoma","enrollment":50},{"nctId":"NCT03555955","phase":"PHASE1","title":"A Trial to Evaluate the Potential Impact of Renal Impairment on the Pharmacokinetics and Safety of CPX-351","status":"COMPLETED","sponsor":"Jazz Pharmaceuticals","startDate":"2018-11-20","conditions":"Hematologic Malignancy, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia","enrollment":21},{"nctId":"NCT04920500","phase":"NA","title":"Bioequivalence of Daunorubicin Cytarabine Liposomes in Naive AML Patients","status":"UNKNOWN","sponsor":"CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.","startDate":"2020-09-04","conditions":"Acute Myeloid Leukemia","enrollment":16},{"nctId":"NCT00671658","phase":"PHASE2","title":"Modified Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) Program for Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2002-11","conditions":"Leukemia, Acute Lymphoblastic Leukemia","enrollment":220},{"nctId":"NCT00632827","phase":"PHASE2","title":"Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)","status":"TERMINATED","sponsor":"University of California, San Francisco","startDate":"2008-07-01","conditions":"Peripheral T-Cell Lymphoma","enrollment":21},{"nctId":"NCT02419469","phase":"PHASE2","title":"Augmented Berlin-Frankfurt-Munster Therapy Plus Ofatumumab for Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-11-13","conditions":"Leukemia, Precursor-B Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma","enrollment":1},{"nctId":"NCT01804101","phase":"NA","title":"Liposomal Cytarabine-Daunorubicin CPX-351 in Treating Patients With Untreated Myelodysplastic Syndrome or Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2013-05-07","conditions":"Acute Biphenotypic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":48},{"nctId":"NCT02269579","phase":"PHASE2","title":"Pharmacokinetic and Pharmacodynamic Assessment of Treatment With CPX-351 (Cytarabine: Daunorubicin) Liposome for Injection in Acute Leukemias and MDS Patients With Moderate Hepatic Impairment","status":"WITHDRAWN","sponsor":"Jazz Pharmaceuticals","startDate":"2015-04","conditions":"Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Myelodysplastic Syndrome (MDS)","enrollment":""},{"nctId":"NCT00098839","phase":"PHASE1, PHASE2","title":"Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL)","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2005-02","conditions":"Recurrent Childhood Acute Lymphoblastic Leukemia","enrollment":134},{"nctId":"NCT02533115","phase":"","title":"EAP of CPX-351 (VYXEOS) for Patients 60-75 Years of Age With Secondary AML","status":"APPROVED_FOR_MARKETING","sponsor":"Jazz Pharmaceuticals","startDate":"","conditions":"Secondary AML","enrollment":""},{"nctId":"NCT00873093","phase":"PHASE2","title":"Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2009-03","conditions":"B-cell Adult Acute Lymphoblastic Leukemia, B-cell Childhood Acute Lymphoblastic Leukemia, Recurrent Adult Acute Lymphoblastic Leukemia","enrollment":148}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Liposomal cytarabine-daunorubicin for injection","genericName":"Liposomal cytarabine-daunorubicin for injection","companyName":"CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.","companyId":"cspc-zhongnuo-pharmaceutical-shijiazhuang-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This liposomal formulation delivers cytarabine and daunorubicin directly into leukemic cells, where both drugs inhibit DNA synthesis and induce apoptosis. Used for Acute myeloid leukemia (AML), Acute lymphoblastic leukemia (ALL), Lymphomatous meningitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}